Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial evaluating the long-term efficacy and peripheral sensory neuropathy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.
Hata T, Uemura M, Danno K, Yoshioka S, Matsuda C, Kagawa Y, Shingai T, Suzuki Y, Tei M, Tanida T, Komori T, Okamura S, Ota H, Takemoto H, Ogino T, Miyoshi N, Yamamoto H, Murata K, Doki Y, Eguchi H. Hata T, et al. Among authors: takemoto h. Sci Rep. 2024 Nov 2;14(1):26434. doi: 10.1038/s41598-024-73222-0. Sci Rep. 2024. PMID: 39488510 Free PMC article. Clinical Trial.
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H. Kono T, et al. Among authors: takemoto h. Cancer Chemother Pharmacol. 2013 Dec;72(6):1283-90. doi: 10.1007/s00280-013-2306-7. Cancer Chemother Pharmacol. 2013. PMID: 24121454 Free PMC article. Clinical Trial.
A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer.
Mizushima T, Ide Y, Murata K, Ohashi I, Yasumasa K, Fukunaga M, Takemoto H, Tamagawa H, Hasegawa J, Hata T, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Mizushima T, et al. Among authors: takemoto h. Oncology. 2013;85(6):317-22. doi: 10.1159/000356018. Epub 2013 Nov 12. Oncology. 2013. PMID: 24247419 Clinical Trial.
Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
Hasegawa J, Nishimura J, Mizushima T, Miyake Y, Kim HM, Takemoto H, Tamagawa H, Noura S, Fujii M, Fujie Y, Kato T, Miwa H, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Hasegawa J, et al. Among authors: takemoto h. Cancer Chemother Pharmacol. 2014 May;73(5):1079-87. doi: 10.1007/s00280-014-2417-9. Epub 2014 Mar 5. Cancer Chemother Pharmacol. 2014. PMID: 24595805
Safety of fondaparinux to prevent venous thromboembolism in Japanese patients undergoing colorectal cancer surgery: a multicenter study.
Hata T, Yasui M, Murata K, Okuyama M, Ohue M, Ikeda M, Ueshima S, Kitani K, Hasegawa J, Tamagawa H, Fujii M, Ohkawa A, Kato T, Morita S, Fukuzaki T, Mizushima T, Sekimoto M, Nezu R, Doki Y, Mori M; Multi-Center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). Hata T, et al. Surg Today. 2014 Nov;44(11):2116-23. doi: 10.1007/s00595-014-0911-7. Epub 2014 May 20. Surg Today. 2014. PMID: 24840400 Free PMC article.
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y, Fukuzaki T, Kudo T, Miyake Y, Yasui M, Morita S, Sakai D, Uemura M, Hata T, Takemasa I, Mizushima T, Ohno Y, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M; Multi-center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). Nishimura J, et al. Among authors: takemoto h. Eur J Cancer. 2015 Jul;51(10):1274-82. doi: 10.1016/j.ejca.2015.03.024. Epub 2015 Apr 24. Eur J Cancer. 2015. PMID: 25922233 Clinical Trial.
First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer.
Uemura M, Kim HM, Hata T, Sakata K, Okuyama M, Takemoto H, Fujii H, Fukuzaki T, Morita T, Hata T, Takemasa I, Satoh T, Mizushima T, Doki Y, Mori M; Multi-Center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). Uemura M, et al. Among authors: takemoto h. Mol Clin Oncol. 2016 Aug;5(2):375-379. doi: 10.3892/mco.2016.938. Epub 2016 Jun 17. Mol Clin Oncol. 2016. PMID: 27446583 Free PMC article.
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea.
Takemoto H, Nishimura J, Komori T, Kim HM, Ota H, Suzuki R, Ikenaga M, Ikeda M, Yamamoto H, Satoh T, Hata T, Takemasa I, Mizushima T, Doki Y, Mori M; Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). Takemoto H, et al. Int J Clin Oncol. 2017 Feb;22(1):88-95. doi: 10.1007/s10147-016-1022-9. Epub 2016 Jul 27. Int J Clin Oncol. 2017. PMID: 27465476 Clinical Trial.
318 results